Given the geographical breadth of the study, results are only rolling in and rigorous analysis will not begin until all results are accounted for. That is what I think anyway, from working on studies like this., but that was 17 years ago and data strategies, I hope, have gotten more efficient.
I enjoy the price and volume action in the last week, a mere foreshadowing of what it will do after results are reported.
If I were a fund manager I would be watching this very closely for a ground floor investment.
slege-Upon completion of the trial Isn't all the data already recorded by each and every patient by the numerical CDAI scores that they noted each week during the trial? I am naive here but what else is there really to do other than to do the math for numbers that have already been recorded? I am not saying the math is simple especially wrt whatever formulas are used to calculate statistical significance, but as far as determining whether endpoints are met, once the data is collected shouldnt it be a quick process? (not questioning your assertion that the data may trickle in from various tx centers). This is a sincere question I am not questioning your comment.
Maybe some short squeezing (maybe not). I always doubted shorts would stay in for the results. Still unsure if I am right or wrong. They possibly covering and with 5M short and if 70 cents squeezed on only 400k volume...well if that is what's happening lets just say there is a lot of juice left in these lemons...